Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Not yet recruiting 3Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 128Breast Neoplasms 95Colorectal Neoplasms 62Carcinoma, Hepatocellular 59Stomach Neoplasms 49Squamous Cell Carcinoma of Head and Neck 47Lung Neoplasms 44Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Triple Negative Breast Neoplasms 42Small Cell Lung Carcinoma 40Uterine Cervical Neoplasms 37Rectal Neoplasms 36Pancreatic Neoplasms 31Neoplasms 29Neoplasm Metastasis 29Recurrence 26Esophageal Squamous Cell Carcinoma 25Ovarian Neoplasms 23Esophageal Neoplasms 23Nasopharyngeal Carcinoma 21Brain Neoplasms 21Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Carcinoma, Renal Cell 20Melanoma 19Endometrial Neoplasms 19Biliary Tract Neoplasms 18Head and Neck Neoplasms 17Multiple Myeloma 16

Interventions

tislelizumab 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × SCLC, Extensive Stage × Clear all
NCT06793228 2025-01-27

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Henan Cancer Hospital

Phase 2 Not yet recruiting
250 enrolled
Thoracic

SCLC, Extensive Stage

NCT06768307 2025-01-10

Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
60 enrolled
Thoracic

SCLC, Extensive Stage

NCT06620796 2024-10-01

A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting
70 enrolled
Thoracic

SCLC, Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡